Top

Langenbeck's Archives of Surgery

Published in:

01-08-2012

Importance of the development time of isolated bone metastasis in breast cancer

Author: Sevim Turanli

Published in: Langenbeck's Archives of Surgery | Issue 6/2012

Abstract

Background and aims

To investigate whether isolated bone metastases at the time of diagnosis is a different entity than bone metastases after breast cancer surgery.

Patients and methods

One hundred thirty-nine patients were examined between June 2004 and January 2007. These patients were classified into synchronous (group I) and metachronous groups (group II) depending on time to development of bone metastases. Patients and tumor characteristics, treatment, clinical progression, and survival were compared for each group.

Results

There were 44 patients in group I and 95 patients in group II. The median follow-up time was 36 months. The two groups showed similar results when patients, tumor characteristics, and clinical progression were compared. In the groups, the median time to progression was 14 vs 13 months (p = 0.70), and median overall survival was 47 vs 46 months (p = 0.96), respectively.

Conclusion

Development time of bone metastasis has no effect on clinical progression, time to progression, and overall survival in breast cancer.

Coleman RE, Smith P, Rubens RD (1998) Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 77(2):336–340PubMedCrossRef

Galasko CSB (1981) The anatomy and pathways of skeletal metastases. Bone metastases. Hall Medical Publishers, Boston, pp 49–63

Khan SA, Stewart AK, Morrow M (2002) Does aggressive local therapy improves survival in metastatic breast cancer? Surgery 132(4):620–626PubMedCrossRef

Babiera GV, Rao R, Feng L et al (2006) Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 13(6):776–778PubMedCrossRef

Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM (2008) Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 247(5):732–738PubMedCrossRef

Rapiti E, Verkooijen HM, Vlastos G et al (2006) Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 24(18):2743–2749PubMedCrossRef

Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD (2001) Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer 91(1):17–24PubMedCrossRef

Briasoulis E, Karavasilis V, Kostadima L, Ignatiadis M, Fountzilas G, Pavlidis N (2004) Metastatic breast carcinoma confined to bone: portrait of a clinical entity. Cancer 101(7):1524–1528PubMedCrossRef

Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN (2001) Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6(2):133–146PubMedCrossRef

10.

Carmichael AR, Anderson ED, Chetty U, Dixon JM (2003) Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol 29(1):17–19PubMedCrossRef

11.

Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA (2007) Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. Ann Surg Oncol 14(8):2187–2194PubMedCrossRef

12.

Grene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual 6th ed. Springer-Verlag, New York

13.

Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100(1):44–52PubMedCrossRef

14.

Andre F, Slimane K, Bachelot T et al (2004) Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22(16):3302–3308PubMedCrossRef

15.

Sherry MM, Greco FA, Johnson DH, Hainsworth JD (1986) Metastatic breast cancer confined to the skeletal system. An indolent disease. Am J Med 81(3):381–386PubMedCrossRef

16.

Dauplat J, Le Bouëdec G, Pomel C, Scherer C (2000) Cytoreductive surgery for advanced stages of ovarian cancer. Semin Surg Oncol 19(1):42–48PubMedCrossRef

17.

Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63(11–12):1727–1733PubMed

Title: Importance of the development time of isolated bone metastasis in breast cancer
Author: Sevim Turanli
Publication date: 01-08-2012
Publisher: Springer-Verlag
Published in: Langenbeck's Archives of Surgery / Issue 6/2012
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-009-0561-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Importance of the development time of isolated bone metastasis in breast cancer

Abstract

Background and aims

Patients and methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background and aims

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2012

Cysto-biliary communication in liver hydatidosis

Combined posterior and anterior approach to the superior mesenteric artery : the advantages of the “hanging maneuver”

Preneoplastic conditions underlying bile duct cancer

Total laparoscopic partial pancreatoduodenectomy and reconstruction via laparoscopic pancreatogastrostomy

Toluidine blue for the intraoperative staining of the ureters. Studies on the safe administration in rats

Prognosis of resected pancreatic cancer: is the refined resection margin status dispensable?